Two of the big companies regarding the manufacture of prime matters and chemical products for the sector of the cosmetic have presented already the results of his activity of the third quarter of 2022. So much BASF like MERK have noticed in his last figures the negative impact caused the global situation of uncertainty and unsteadiness that lives at present.
On the one hand, BASF has announced by means of his press release that has not fulfilled with the planned expectations regarding profits and that will initiate a plan of saving until finals of 2024 to save 500 million euros.
The German company obtained gains of 21,900 million euros, 12% more than the same quarter of the previous year, although this growth comes caused, as they recognize in the press release, by an increase of prices in almost all the segments. The gains improved considerably in the segments of final products and reduced significantly in the segments of Chemical and Material Products. The result of exploitation before extraordinary reduced in 517 million euros in comparison to the same period of time that the past year and the president of the board of BASF declared that the segments of final products Technologies of Surface, Agricultural Solutions, Nutrition, and Care and Industrial Solutions increased his gains of considerable form.
The flows of operative box increased until attaining the 2,300 million euros, an increase of 400,000 euros with regard to the 1,900 mill of the third quarter of the past 2021. BASF Keeps the perspectives for the last quarter of the year, in which it foresees some sales that reach between 86,000 million euros and the 89.000, with an EBIT before extraordinary that oscillate between the 7,000 million euros.
BASF took advantage of the announcement of the economic results and with a context of gains something feebler in Europe, and especially in Germany, where the results of this quarter have been negative by the rise of the cost of the energy, has communicated that will initiate a program of saving.This program is of immediate application in this last quarter of 2022 and will apply until finals of the next 2024. With him, Martin Brudermüller has cleared that pretends to face up to the increase of the price of the gas, of the energy and to the feeble growth that has experienced during a decade the market of chemical products. From BASF, aim to that have had to face up to an additional cost of 2.200 million euros only for the supply of gas in the centers of Europe.
Merck, for his part, explained that in this third quarter of 2022 has seen its sales have grown 16.8% to reach 5.806 million euros. These sales have had an organic increase of 7.1%. This growth is especially in what the company lists as "The Big 3": 'Process Solutions and Life Science Services', new products from 'Healthcare' and 'Semiconductor solutions'. According to their press release, they are the keys to this strong flood.
"Despite the continuing turbulence in our external operating environment, we have demonstrated our resilience and achieved strong organic growth in sales and previous EBITDA in the third quarter of 2022" said Belén Garijo, President of the Merck Executive Board and CEO. "The three business sectors are well positioned. In Life Sciences, the core business generated double-digit growth, more than offsetting the expected decline in pandemic-related sales. The new products and portfolio established at Healthcare performed well. And in Electronics, the renewed double-digit growth of Semiconductor Solutions justifies our confidence in this business."
Pre EBITDA, the most important financial indicator used to run the operating business, soared 16.7% to €1.810 billion. This key figure grew organically by 7.5%, driven by the business sectors of 'Life Science' and 'Healthcare'. Pre EBITDA was favorably influenced by the foreign exchange effects of 8.8% and a portfolio effect of 0.5% of the acquisition of Exelead, an American biopharmaceutical company that Merck bought for 687 million euros in February.
As indicated in its press release, Merck boosted a strong investment in innovation and technology in its three business lines: 'Life Science', 'Healthcare' and 'Electronics'. The latter represents 1,036 million euros of the sales figure in this quarter, the segment of 'Healthcare' is 2,089 million euros, while in 'Life Science' it amounts to 2,681 million euros.